This content is restricted.
Brief
On March 21, 2025, the National Health Surveillance Agency (Anvisa) issued an update regarding RPBR: Check out the list of active ingredients that will be evaluated in 2025. The update includes information on the periodicity and requirements for the submission of Relatórios Periódicos de Avaliação Benefício-Risco (RPBR), a document outlining the evaluation of the benefit-risk profile of registered medicines, as mandated by RDC nº 406/2020 and IN nº 63/2020.
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested